{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Enrollment",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_2",
        "name": "CRU Admission Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_3",
        "name": "Diet Equilibration Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Pretreatment Balance Measurement",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_5",
        "name": "Initial 15mg/day Collection Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_6",
        "name": "CRU Discharge Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "CRU Re-admission Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Second Collection Period (15mg and 30mg)",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 25,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_10",
        "name": "Urine Pregnancy Test Frequency",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_11",
        "name": "CRU Inpatient Period 2 End",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 40,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Zinc Washout",
        "instanceType": "Condition",
        "description": "Participants must discontinue zinc therapy for a minimum period before Day 1.",
        "text": "Previous treatment with zinc within 21 days prior to Day 1."
      },
      {
        "id": "cond_2",
        "name": "Chelator Washout",
        "instanceType": "Condition",
        "description": "Participants must discontinue chelator therapy prior to initiating ALXN1840.",
        "text": "Participants will be discontinued from their chelator therapy for approximately 4 days prior to initiating ALXN1840."
      },
      {
        "id": "cond_3",
        "name": "Experimental Therapy Washout",
        "instanceType": "Condition",
        "description": "Participants must have a washout period from other experimental therapies.",
        "text": "The use of an experimental or unapproved/unlicensed therapy at the same time or within 90 days or 5 half-lives, whichever is longer, prior to the Screening Visit."
      },
      {
        "id": "cond_4",
        "name": "Prescription Medication Washout",
        "instanceType": "Condition",
        "description": "Participants must abstain from prescription medications prior to Day -7.",
        "text": "Participants must abstain from taking prescription medications within 14 days or 5 half-lives (whichever is longer) of Day -7."
      },
      {
        "id": "cond_5",
        "name": "Non-Prescription Medication Washout",
        "instanceType": "Condition",
        "description": "Participants must abstain from non-prescription drugs, vitamins, and supplements prior to Day -7.",
        "text": "Participants must abstain from nonprescription drugs (including vitamins and dietary or herbal supplements) within 7 days or 5 half-lives (whichever is longer) before Day -7."
      },
      {
        "id": "cond_6",
        "name": "Safety Review for Dose Titration",
        "instanceType": "Condition",
        "description": "Safety data must be reviewed by the SRC before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_7",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The outpatient period may be extended with Investigator approval.",
        "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_8",
        "name": "ALT > 5x ULN",
        "instanceType": "Condition",
        "description": "Criterion for dose discontinuation based on Alanine Aminotransferase levels.",
        "text": "ALT > 5 × ULN"
      },
      {
        "id": "cond_9",
        "name": "ALT > 3x ULN",
        "instanceType": "Condition",
        "description": "Criterion for dose interruption based on Alanine Aminotransferase levels.",
        "text": "ALT > 3 × ULN"
      },
      {
        "id": "cond_10",
        "name": "Hematologic Abnormality",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction based on hemoglobin, platelets, or neutrophils.",
        "text": "Hemoglobin < 10 g/dL or > 30% decrease from baseline; Platelets < 100,000/mm3 or > 30% decrease from baseline; Neutrophils > 30% decrease from baseline and below reference range."
      },
      {
        "id": "cond_11",
        "name": "Potential Liver Injury (Hy's Law)",
        "instanceType": "Condition",
        "description": "Criterion for temporary dose interruption based on bilirubin and ALT levels.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN"
      },
      {
        "id": "cond_12",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Clinical evidence of neurologic worsening triggers a review for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment."
      },
      {
        "id": "cond_13",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Clinical evidence of psychiatric worsening triggers a review for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_14",
        "name": "Serious Hypersensitivity Reaction",
        "instanceType": "Condition",
        "description": "A serious hypersensitivity reaction requires discontinuation of study intervention.",
        "text": "Serious hypersensitivity reaction"
      },
      {
        "id": "cond_15",
        "name": "Severe Uncontrolled Infection",
        "instanceType": "Condition",
        "description": "A severe uncontrolled infection requires discontinuation of study intervention.",
        "text": "Severe uncontrolled infection"
      },
      {
        "id": "cond_16",
        "name": "Use of Disallowed Medication",
        "instanceType": "Condition",
        "description": "Use of a disallowed medication requires discontinuation of study intervention.",
        "text": "Use of disallowed medication"
      },
      {
        "id": "cond_17",
        "name": "Pregnancy",
        "instanceType": "Condition",
        "description": "Pregnancy or planned pregnancy requires discontinuation of study intervention.",
        "text": "Pregnancy or planned pregnancy"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Titration Hold",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_15mg_extended",
        "text": "Participants may remain on the 15 mg/day dose for the duration of the study if there are safety concerns."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for ALT > 3x ULN",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT > 3x ULN, dosing is temporarily interrupted."
      },
      {
        "id": "trans_4",
        "name": "Discontinuation for ALT > 5x ULN",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT > 5x ULN, discontinue study intervention."
      },
      {
        "id": "trans_5",
        "name": "Dose Reduction for Hematologic Abnormality",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin, Platelets, or Neutrophils meet criteria, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_6",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN and ALT > 3x ULN, dosing is temporarily interrupted."
      },
      {
        "id": "trans_7",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
      },
      {
        "id": "trans_8",
        "name": "Intervention Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy; or if Alexion or the Investigator deems it necessary."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretion Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to titrate dose from 15 mg/day to 30 mg/day, based on safety review.",
        "conditionIds": [
          "cond_6"
        ]
      },
      {
        "id": "dec_2",
        "name": "Dose Modification Decision",
        "timepointId": "Unscheduled",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Unscheduled decision point to modify, interrupt, or discontinue dose based on safety lab results or clinical worsening.",
        "conditionIds": [
          "cond_8",
          "cond_9",
          "cond_10",
          "cond_11",
          "cond_12",
          "cond_13"
        ]
      },
      {
        "id": "dec_3",
        "name": "Intervention Discontinuation Decision",
        "timepointId": "Unscheduled",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to permanently discontinue study intervention based on specific events.",
        "conditionIds": [
          "cond_14",
          "cond_15",
          "cond_16",
          "cond_17"
        ]
      }
    ],
    "summary": {
      "timingCount": 11,
      "conditionCount": 17,
      "transitionRuleCount": 8,
      "exitCount": 5
    }
  }
}